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MaAs with new drugs, the U.S. Food and Drug Administration’s approval process is intended to provide consumers with
assurance that, once it reaches the market place, a medical device is safe and effective in its intended use. Bringing a
device to market takes an average of 3 to 7 years, compared with an average of 12 years for drugs. However, there are
concerns that Food and Drug Administration processes may not be sufﬁcient to meet the assurances of safety and ef-
ﬁcacy as intended. This second part of a 2-part series reviews the basic steps in development and Food and Drug
Administration approval of medical devices, and summarizes post-marketing processes for drugs and devices. (J Am Coll
Cardiol Basic Trans Science 2016;1:277–87) ©2016 The Authors. Published by Elsevier on behalf of the American College of
CardiologyFoundation. This is anopen access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).I n the early part of the 20th century, the U.S. Foodand Drug Administration (FDA) was given theresponsibility for ensuring both the safety and
efﬁcacy of drugs prior to marketing (1). Amendments
to the Federal Food Drug and Cosmetics Act in 1976
expanded the agency’s role to oversee safety in the
development of medical devices (2). Whereas new
drug approval takes an average of 12 years, moving
new medical devices from concept to market takes an
average of 3 to 7 years (3). This is the second part of a
2-part series on U.S. drug and device approval pro-
cesses, and it reviews the basic steps in moving a
medical device from conception to market, as well as
post-market surveillance for both drugs and devices.
As will be discussed, there are unique regulatory is-
sues that are related to the device approval process.
WHAT IS A DEVICE?
Devices are regulated by the Center for Devices and
Radiological Health (CDRH) at the FDA. According tom the Department of Anesthesiology and Pain Medicine, University of W
eived ﬁnancial support from the American College of Cardiology.
nuscript received March 18, 2016; revised manuscript received March 31,the Federal Food Drug and Cosmetics Act, a device is
“an instrument, apparatus, implement, machine,
contrivance, implant or an in vitro reagent” that
meets 3 conditions: 1) it is recognized in the ofﬁcial
National Formulary or the U.S. Pharmacopeia; 2) it is
intended for use in the diagnosis of disease or other
conditions, or the cure, mitigation, treatment, or
prevention of disease; or 3) it is intended to affect the
structure or function of the body of humans (4).
Devices cannot achieve their ends by chemical action
or be dependent on metabolism (5). Some products
that contain biological material are inert (e.g., acel-
lular dermatologic ﬁllers [6]) and can actually be
considered devices. The range of objects that falls
under the FDA deﬁnition of medical devices is broad,
from tongue depressors and stethoscopes, to lab
equipment, surgical instruments, and life-support
equipment such as pacemakers, ventilators, and
perfusion devices. If in doubt about whether a prod-
uct is a device or a biological, the Device Determina-
tion Ofﬁcer at the FDA can be of assistance (7).ashington, Seattle, Washington. Dr. Van Norman has
2016, accepted March 31, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
CDRH = Center for Devices and
Radiological Health
eCopy = electronic copy
FDA = Food and Drug
Administration
HDE = humanitarian device
exemption
HUD = humanitarian use device
IDE = investigational device
exemption
IRB = institutional review
board
PMA = pre-market approval
PMN = pre-market notiﬁca
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278THE PRE-CLINICAL STAGES:
PROTOTYPE DEVELOPMENT
AND TESTING
Many medical devices coming to market
represent successive iterations of previous
devices. Development of an entirely new
device typically begins with a concept by a
physician or bioengineer for a solution to
a medical problem. They build or arrange
to have built a preliminary prototype of
the device and simultaneously initiate a
patent process. Preliminary bench testing is
followed by animal testing, and the device
enters a cycle of testing and redesign that
typically takes 2 to 3 years and costs between$10 million and $20 million. Largely because of these
costs, today most truly new medical devices arise out
of venture-backed startup companies rather than
academic medical centers (8).
REQUIREMENTS FOR CLINICAL TRIALS
Devices are classiﬁed into 3 groups by the FDA: Class I
or “low risk of illness or injury” (e.g., surgical gauze
[9]); Class II or “moderate risk” (e.g., suture [10]); and
Class III, those which “support or sustain human life,
are of substantial importance in preventing impair-
ment of human health, or present a potential,
unreasonable risk of illness or injury” (e.g., pace-
makers [11]). Class I and II devices are subject to less
stringent regulatory processes than Class III devices
are; Class I or II device approvals are focused on
registration, manufacturing, and labeling and often
do not require extensive pre-clinical or clinical data.
Class III devices that have only minor differences
from already approved, so-called predicate devices,
may be reclassiﬁed as Class I or II and are also subject
to less stringent testing requirements than most Class
III devices that are without predicates.
Around three-fourths of Class I devices, and a small
percentage of class II devices qualify for “exempt”
status, meaning there is no need for proof of safety or
efﬁcacy, nor for clinical trials (12). They also do not
need to undergo the standard pre-market notiﬁcation
(PMN) process. Most Class II devices, however, have
to demonstrate that they will perform as expected
and will have to go through a PMN (aka 501[k])
clearance, which will likely not require stringent
clinical evidence.
Class III devices pose signiﬁcantly greater risks to
patients and typically require pre-market approval
(PMA), the most rigorous process required for devices
by the FDA. Such devices will require clinical
tionevidence to support the application. If a Class III de-
vice represents only minor changes from an already
existing, approved device (or “predicate” device), it
may not require the strict PMA process, and the
sponsor can petition the FDA to reassign the device
by means of a 513(g) application (13). Such devices
can generally be approved by the less rigorous
501(k) process.
In general, all new devices that do not have such a
predicate are automatically classiﬁed Class III by
default and are required to undergo the most strin-
gent reviews that include provision of clinical evi-
dence and trials. However, a sponsor may also apply
directly to the FDA to reclassify devices that do not
have predicates to Class I or II if the device is of low
to moderate risk (14). Such devices are termed
“de novo” devices and are managed much like
devices with predicates in a less rigorous process. A
summary of devices and regulatory pathways can be
seen in Table 1.
3 BASIC PATHWAYS TO
MEDICAL DEVICE APPROVAL
There are 3 basic processes to obtain FDA marketing
approval for medical devices, depending on the
nature of the device and the circumstances under
which approval is sought: 1) the PMA process; 2) the
PMN process; and 3) the humanitarian device
exemption (HDE) process.
PATHWAY 1: PRE-MARKET APPROVAL (PMA). Device
manufacturers are required by federal law to notify
the FDA of their intent to market a medical device at
least 90 days prior to marketing. A PMA (15) is the
strictest device marketing application and is required
by the FDA for any new device for which there is
no existing equivalent or predicate, unless such a
device can be reclassiﬁed as a “de novo” device.
In a PMA, a device must be shown to have sufﬁcient
scientiﬁc evidence that it is safe and effective in its
intended use.
As with drug approvals, the FDA has a pre-
submission process to facilitate PMA and 510(k)
applications (16), and it encourages sponsors and
investigators to establish early contact and collabo-
ration with the appropriate review division in
“Pre-submission” meetings, also known as “Q-sub”
meetings (17). In certain cases, in collaboration with
the FDA, a modiﬁed form of PMA may be allowed. One
example is a “modular PMA” (18) in which sections
of the application are submitted inmodules as they are
completed, a method usually reserved for devices in
early stages of clinical studies. A current pilot
program of the FDA within the Division of Clinical
TABLE 2 Levels of Evidence for a Clinical Therapeutic Study
Level I
 High-quality RCT (e.g., >80% follow-up, double-blinded) with
statistically signiﬁcant different or no statistically signiﬁcant
difference by narrow CI
 Level I RCT or systematic review and results were homogeneous
Level II
 Lesser quality RCT (<80% follow-up, not blinded,
poor randomization)
 Prospective comparison studies
 Systematic review of Level II studies or of Level I studies with
inconsistent results
Data from DeVries and Berlet (20).
CI ¼ conﬁdence interval; RCT ¼ randomized controlled trial.
TABLE 1 Classes of Medical Devices
Risk Regulatory Pathway
Class I (e.g., gauze,
toothbrushes)
Low risk of illness
or injury
75% are exempt from approval
Class II (e.g., suture,
needles)
Moderate risk of
illness or injury
The majority will have to go through a PMN
application
Known Class III
(e.g., pacemakers,
ventilators)
Signiﬁcant risk of
illness or injury
Has a predicate device
and may be able to
undergo PMN rather
than the full PMA
process
Does not have a
predicate and
generally must go
through the PMA
process device
New devices classiﬁed
as Class III by
default
If low or moderate risk, investigator may petition
to have them classiﬁed as “de novo” devices,
and they may be able to undergo a PMN
process rather than full PMA process
PMA ¼ pre-market approval; PMN ¼ pre-market notiﬁcation.
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279Laboratory Devices is called the “streamlined”
PMA (19). This PMA can be useful if the FDA has
already had experience with reviewing similar
devices. Whether a PMA can be “streamlined” or sub-
mitted as a modular application can be determined in
the pre-submission process and may substantially
reduce the time and effort to obtain approval for some
devices.
Cl in ica l ev idence requ i rements . In general, Level
I or II evidence is required to obtain FDA approval of
most new class III devices (Table 2) (20,21). In order to
conduct pre-market clinical trials with the device,
investigators must ﬁrst obtain an investigational de-
vice exemption (IDE), summarized in Table 3 (17,22).
Although the FDA is obliged to respond to an appli-
cation within 30 days, U.S. regulations regarding de-
vice development and testing in fact typically add
about 3 to 6 months to obtain FDA approval to carry
out clinical studies, plus 3 to 6 months for institu-
tional review board (IRB) approval at the clinical site.
As a result, up to 75% of initial clinical testing of de-
vices has moved outside of the United States (8).
Clinical testing typically involves a series of
studies from ﬁrst-in-human use, to large, multicenter
prospective, randomized control trials (“pivotal”
trials). Pivotal trials may require up to 1,000 subjects
over a period of 1 to 2 years and follow-up for 1 year
after treatment (8). The complexity of the required
trials depends on the nature of the device and its
proposed use.
In May 2015, the U.S. House of Representatives
passed the 21st Century Cures Act (23) that, in addi-
tion to other measures, permits certain medical de-
vice approvals on the basis of observational studies
and “clinical experience” rather than randomized
controlled trials. The act was intended to reduce the
time and expense of device approval, but it has raised
serious concerns about whether the safety and efﬁ-
cacy of medical devices will be compromised (24,25).
Whatever the pathway of approval, early collabo-
ration with the FDA via its pre-investigational device
program is strongly advised (26); investigators can
present existing data (pre-clinical data and clinical
data from foreign studies) to the FDA in pre-
investigational meetings and obtain suggestions
from the CDRH regarding the need for additional pre-
clinical data and for clinical study design prior to
applying for the IDE (8). The speciﬁcs of study design
can severely affect the time and cost of getting a
medical device approved, and discussions with the
FDA can be useful in negotiating clinical endpoints
for studies.
The PMA rev iew. PMA and PMN (aka 510[k]) appli-
cations for medical devices are reviewed by the CDRHwithin the FDA. Within that center are the Ofﬁce
of Device Evaluation and the Ofﬁce of In Vitro
Diagnostics and Radiological Human Health. Within
these ofﬁces, the divisions are organized according to
device specialties.
After receipt of a PMA, the FDA determines
whether the application is sufﬁciently complete to
begin a substantive review. The agency has 45 days to
make this determination, ﬁle the application, and
notify the applicant of the ﬁling. The notiﬁcation
letter will include an assigned PMA reference number
and the actual date of ﬁling. The FDA then has 180
days from the date of ﬁling for the PMA review. If the
FDA refuses a PMA due to insufﬁciencies, it will
assign a PMA reference number and notify the
applicant within 45 days of the refusal regarding
reasons for refusal. The applicant may supply further
information, and the 180-day “clock” resets when the
resubmission is ﬁled. Alternatively, the applicant can
request an informal conference with the director of
the Ofﬁce of Device Evaluation to review the decision
within 10 working days of receipt of notiﬁcation of
refusal. The FDA must decide to ﬁle or refuse the
submission within 5 working days of the conference.
TABLE 3 IDE Process
Step 1. Investigator contacts the pre-
investigational device exemptions
program and requests a pre-submission
meeting (these are called “pre-sub” or
“Q” meetings).
Time frame from submission to scheduled
meeting is 75–90 days, or 21 days in
cases of urgent public health need.
 Collaboration with the FDA at this stage can
determine whether further clinical testing is
necessary and can produce nonbinding but
important suggestions regarding clinical
studies and clinical design. Information
about collaborative meetings and
requests can be found at: http://www.
fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/ucm073604.htm.
 Submit requests for a “pre-sub” meeting to:
U.S. Food and Drug Administration
Centers for Devices and Radiological Health
Document Control Center W066-G609
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
Step 2. Investigator submits a complete
IDE application (FDA §812.20
application).
Time from submission to response:
30 days. (If no response is received
30 days after conﬁrmation from
the FDA of receipt of application,
investigations can proceed)
 Currently this requires both a hardcopy of
the application and an electronic copy
(eCopy) on CD, DVD, or ﬂash drive.
 There is no application form. Speciﬁcs
of the content and format of the IDE
application, as well as checklists for content
of the IDE application can be found at:
http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
HowtoMarketYourDevice/
InvestigationalDeviceExemptionIDE/
ucm046706.htm.
 Submissions should be addressed to:
Food and Drug Administration
Center for Devices and Radiological
Health
Document Mail Center - WO66-G609
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
Step 3. While waiting for response, submit
application for IRB approval at the local
institutions where all investigations are
to be carried out.
Step 4. What to do if a “hold” notiﬁcation is
received from the FDA prior to 30 days.
 Review the “hold” letter for speciﬁc reasons
the application is placed on hold.
 Contact the FDA to discuss how to address
“hold” rationale.
FDA ¼ Food and Drug Administration; IDE ¼ investigational device exemption; IRB ¼ institutional review board.
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CDRH. The director’s decision is ﬁnal (15).
PATHWAY 2: PRE-MARKETING NOTIFICATION (PMN):
THE 510(K) APPLICATION. A PMN, also known as a
510(k) application (8,12,27), is a fast-track process for
devices in which the sponsor shows that the device is
substantially equivalent to an existing device that is
already approved and marketed. Devices that are
currently under PMA review but have not been
approved cannot serve as a predicate device in a PMN
for a different, new device. If the FDA determines
that the device has an acceptable predicate, a PMA
application is not needed, and PMN can proceed.
The FDA may determine at the time of application
submission that the proposed predicate does not
qualify and refuse the 501(k) application, and then
a full PMA will be required. The FDA has pro-
vided a decision-making algorithm for determiningsubstantive equivalence of a proposed predicate de-
vice (28). PMN must be submitted to the FDA at least
90 days prior to anticipated marketing.
The PMN process has been criticized as introducing
additional risks to consumers, because the assump-
tion that the device is “equivalent” to another already
marketed device may be unsound. One example is
the Pinnacle metal-on-metal acetabular cup liner
marketed by DePuy Orthopaedics (Raynham,
Massachusetts) was “fast tracked” by the FDA based
on its nearly identical predicate, the Ultima system
(DePuy Orthopaedics), but had to be discontinued in
2013 due to unacceptable rates of patient-adverse
reactions (12).
Another problem with the PMN process is that
“serial predicates” can occur—in other words, a new
device can be approved using as its predicate another
device that was itself approved based upon yet
another, different predicate. This means that a cur-
rent device can be approved based on a PMA that
occurred several “generations” prior to the current
one in a series of similar devices. Decades can pass
between the current device in question and the
original PMA and clinical evidence supporting it.
In 2011, the Institute of Medicine recommended
eliminating the PMN approval process, based on this
speciﬁc concern (29,30). In addition, the Institute
of Medicine recommended enhancing the post-
marketing surveillance system for medical devices.
The Institute of Medicine did not provide speciﬁc
plans for such changes, and the report was met by
protests from manufacturers that the changes would
slow technological innovation, harm patients, and
cost manufacturing jobs (3).
Additional criticisms of the PMN process include
worries that it incentivizes manufacturers to develop
new devices that are only slight improvements over
their forerunners rather than true innovations, but for
which they can nevertheless charge a premium
price as a “new” device (30,31). One example of this
occurred in the development of the Cerecyte coil
marketed by Micrus Endovascular (San Jose, Califor-
nia) for treatment of intracranial aneurysms. The
manufacturer was able to charge a premium for the
device without having to provide prospective evi-
dence that the product was superior to other coils
currently on the market. Later, prospective studies
demonstrated efﬁcacy, but nonsuperiority compared
with existing devices. The result was that overall
costs to patients increased, but for a nonsuperior
product (3).
Finally, the fast-track process has the potential to
slow active enrollment of human subjects in clinical
studies. Manufacturers can receive reimbursement
TABLE 4 Medical Device User Fees per Type of Application for
2016
Standard Fee Small Business Fee
510(k) or PMN $5,228 $2,614
513(g) application for
device reclassiﬁcation
$3,529 $1,765
PMA $261,388 $65,347
Abbreviations as in Table 1.
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evidence regarding efﬁcacy. Therefore, motivation to
complete such studies may be diminished (32).
De novo dev ices . Most new devices that do not have
predicates are automatically classiﬁed as Class III and
must undergo the full PMA process, including the
submission of Class I or II evidence of clinical efﬁ-
cacy. However, sponsors can petition to reclassify
low- or moderate-risk devices that do not have
predicates (and would not ordinarily qualify for
510(k) applications) as “de novo” devices. If a device
is classiﬁed as de novo it can undergo the PMN pro-
cess rather than the more rigorous PMA. Devices
approved as de novo devices can then serve as
predicates for other devices (33).
The PMN rev iew process . In a PMN (27), the
sponsor supplies 2 copies of the application (1 of
which must be an electronic copy or “eCopy”) plus a
user fee to the CDRH’s Document Control Center. A
summary of 2016 user fees for applications can be
found in Table 4 (34,35). If the user fee or eCopy are
not included in the application, a hold will be placed
on the application and a hold letter sent to the sub-
mitter within 7 days. The submitter then has 180
days to resolve issues regarding the fee and eCopy. If
both fee and eCopy are received, the submitter will
receive an acknowledgment letter identifying the
date of receipt of the application and assigning the
application a unique control number, commonly
referred to as a “510K number,” or “K number.” This
letter does not constitute a clearance for marketing,
but is merely a conﬁrmation that a review process
has begun.
Once it is assigned a “K number,” the submission is
then routed to the appropriate CDRH division based
on device type and medical specialty involved.
Within the division, the submission is assigned a lead
reviewer, who conducts an “acceptance review” to
determine that all essential elements of the applica-
tion are complete, so that a substantive review can
begin. The acceptance review is completed, and the
submitter is notiﬁed of the results within 15 days of
receipt of an application, eCopy, and user fee. When
the application is moved to substantive review, the
lead reviewer is also identiﬁed to the submitter.
Within 15 days of notiﬁcation of substantive review,
FDA reviewers must answer some basic questions to
the lead reviewer, including whether the product or a
component thereof is a device, whether the submis-
sion has been made to the appropriate center, whether
the device is of a classiﬁcation that is eligible for a
510(k) submission, and other details. Full details of the
inquiries can be found in the “Refuse to Accept Policy
for 510(k)s” section on the FDA website (16).After basic questions are answered, the FDA must
respond with an approval or denial within 60 days of
the receipt of a complete 501(k) PMN (i.e., within 45
days of acceptance for substantive review) (16).
PATHWAY 3: THE HUMANITARIAN DEVICE EXEMPTION
(HDE). A humanitarian use device (HUD) is one that is
expected to treat or diagnose conditions that affect
fewer than 4,000 individuals in the United States
annually. HDE are handled through the Ofﬁce of
Orphan Products Development at the FDA. The use of
an HUD requires approval and supervision by a local
IRB in addition to approval by the FDA (36). The
application for an HDE is similar to that for a PMA,
except that scientiﬁc evidence of efﬁcacy is not
required, under the rationale that it could take years
to even ﬁnd enough subjects to provide sufﬁcient
power in order for a clinical study to attain statistical
signiﬁcance. The device sponsor is only required to
demonstrate that there is a probable beneﬁt to health,
and that the probable beneﬁt outweighs the risk of
injury or illness caused by the device. In other words,
the HDE requires demonstration of device-relative
safety, but not device efﬁcacy.
To protect particularly vulnerable patient cohorts
from manufacturers who might hope to proﬁt from
devices with unproven efﬁcacy, the price the manu-
facturer can charge for such devices is limited to
covering manufacturing fees, research and develop-
ment expenses, and other closely deﬁned costs. Any
device costing more than $250 must submit a report
from an independent certiﬁed accountant attesting to
the excess cost and reasons for it (36). Some excep-
tions for that rule are provided for devices used in
pediatric populations.
An approved HDE allows use of the HUD, but only at
institutions that have established local IRB to oversee
clinical testing of devices, and only after local IRB
approval. The device labeling must state that it is a
humanitarian device, and that although authorized for
use by federal law, the effectiveness of the device for
the speciﬁc indication has not been demonstrated (36).
The HDE rev iew process . Obtaining an HDE in-
volves 2 steps: obtaining designation of the device as
TABLE 5 Emergency or Expanded Use of Investigational Devices
Time Frame Criteria Application Process
Time to Approval/
Treatment
Emergency use Immediate need  Life-threatening or serious
condition
 No alternative treatment
 No time to get FDA
approval
Submit IDE report to the FDA
of an emergency use
within 5 days of use,
giving details of the case
and patient protection
measures followed
Approval is post hoc
Emergency
research
Prior to initiating a clinical
trial involving emergency
interventions
 Emergency research in
which the human subject of
the research is in a life-
threatening situation and it
is not feasible to get
informed consent
Regular IDE submission
process: in addition to IRB
approval, a physician not
involved in the project
must review and approve
Regular IDE approval
timeline
Compassionate use During clinical trial of the
device; physician wants to
treat a patient who does
not meet trial inclusion
criteria
 Patient with a serious
condition or disease
 No alternative treatment
 Patient does not otherwise
qualify for inclusion in the
clinical study, but the
physician believes they may
beneﬁt
 Usually for use in a single
patient, but can sometimes
be for a small group
FDA approval required before
treatment: sponsor
submits an IDE
supplement requesting
compassionate use under
section §812.35(a)
Regular IDE approval
timeline
Treatment use During clinical trial of the
device; data suggest the
device is effective, and
the investigator wants to
expand the number of
enrollees to include other
patients with life-
threatening or serious
disease
 Life-threatening or serious
disease
 No alternative
 Controlled clinical trial
 Sponsor actively pursuing
market approval
FDA approval required prior to
treatment. Investigator
submits a treatment IDE
application under section
§812.36
Treatment use may
begin 30 days after
the FDA receives
the submission
Continued access After the clinical trial has
concluded: FDA may allow
enrollees to continue to
receive treatment while
the approval process is
underway
 Public health need or
 Preliminary results suggest
the device will be effective,
and no safety concerns
have been identiﬁed for the
proposed indication
Investigator submits an IDE
supplement requesting
continued access or an
extended investigations
permit
Treatment has
presumably begun
during the trial and
continues after
Use of an investigational device in humans is generally restricted to approved clinical studies in accordance with an approved protocol. The FDA has mechanisms for using
unapproved, investigational devices to save the life of a patient, or for patients suffering from serious diseases for which no alternative therapy exists.
Abbreviations as in Table 3.
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The FDA will respond within 45 days of submission of
an application for designation of a device as an HUD
in 1 of 3 ways: 1) approve the device as an HUD; 2) ask
for further information; and 3) refuse the designation.
Refusals are often based on ﬁndings that the condi-
tion for which the HUD is being sought affects >4,000
people annually in the United States. If the device is
designated an HUD by the FDA, the applicant can
submit an application for HDE. The FDA has 30 days
for an acceptance review to determine that the
application is complete enough for a substantive re-
view, and then within 45 days of that notiﬁcation (75
review days total) will respond with a notiﬁcation of
approval, disapproval, or nonapproval (meaning
more information is needed) (37).
EMERGENCY AND EXPANDED APPROVALS FOR USE
OF AN INVESTIGATIONAL DEVICE (IDE). As with
investigational drugs, the FDA has provisions forallowing the use of an investigational (unapproved)
device to save the life of a patient, or to treat a patient
for which there is no alternative therapy available.
Within the application process are 5 potential ways in
which health care providers can obtain approval to
legally use an investigational device for such patients
before it has been approved. These are summarized in
Table 5 (38,39).
OVERVIEW OF HOW TO OBTAIN FDA
APPROVAL FOR A MEDICAL DEVICE
STEP 1: CLASSIFY THE DEVICE. The ﬁrst step for the
sponsor (after determining that the product is a
device) is to classify the device (as Class I, II, or III)
(Central Illustration). Even though the FDA will do this
during the review of the pre-market submission, it is
nevertheless important for the sponsor to do so as
well, because that will determine which submission
CENTRAL ILLUSTRATION FDA Medical Device Approval Pathways*
Van Norman, G.A. J Am Coll Cardiol Basic Trans Science. 2016;1(4):277–87.
*Early consultation with Food and Drug Administration (FDA) through pre-submission meetings in strongly encouraged; the FDA can help
determine which pathway and applications are needed, as well as determine whether clinical trials are necessary. FFDCA ¼ Federal Food, Drug,
and Cosmetics Act; HDE ¼ human device exemption; IDE ¼ investigational device exemption; IRB ¼ Institutional Review Board; PMA ¼ pre-
market approval; PMN ¼ pre-market notiﬁcation.
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283path is appropriate for the device. To facilitate this,
the FDA offers a searchable database with device
classiﬁcations (7). Classiﬁcation of the device will also
determine the regulatory control during and after the
marketing process, important issues for the sponsor
to consider.
If the device is an entirely new device, determine
whether it has a predicate or could be reclassiﬁed a“de novo” device of low to moderate risk that does
not have a predicate. The sponsor can petition the
FDA for reclassiﬁcation of the device and attempt
approval along the 501(k) application pathway.
STEP 2: SELECT THE APPROPRIATE PRE-MARKET
SUBMISSION PATHWAY. Class I devices and many
Class II devices, as well as Class III devices with
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284predicates can usually forego PMA and proceed with a
510(k) application. A PMA is required for most Class
III devices, with valid Level I or II scientiﬁc evidence
providing reasonable assurance of safety and efﬁcacy.
If the device is Class III and intended to beneﬁt fewer
than 4,000 patients annually in the United States,
the investigator should proceed with a request for
designation of the device as an HUD. After receiving
designation as an HUD, the investigator should pre-
pare an HDE application to exempt the device from
having to provide stringent evidence of efﬁcacy.
STEP 3: IF THE DEVICE REQUIRES A FULL PMA.
Clinical trials will be required and the investigator
should prepare an IDE application. The PMA can
proceed after obtaining sufﬁcient Level I and II clin-
ical evidence.
STEP 4: PREPARE THE APPROPRIATE APPLICATION.
The FDA provides resources at their website to direct
sponsors regarding the necessary information,
depending on whether the application is a PMA, a
501(k) PMN, or an HDE. In general, the applicant must
supply information about device indications and
function, basic scientiﬁc concepts, summary of all
adverse safety and efﬁcacy information, procedures to
control risks, alternative procedures and treatments to
the device, summary of pre-clinical and (in the case of
PMA, HDE, and some 501[k]) clinical trial data, and a
bibliography of references. Pre-submission contact
with the FDA for feedback on medical device approval
is highly encouraged.
Prior to initiating any clinical study of the device
for the purpose of a PMA, HDE, or 501(k) application,
the investigator must obtain IDE from the FDA as well
as local IRB approval.
STEP 5: SEND THE SUBMISSION TO THE FDA. Recall
that a user fee and eCopy on a compact disc, digital
video disc, or ﬂash drive are required for acceptance
reviews. Within 15 days of receipt of a submission,
eCopy, and user fee, the FDA will complete an
administrative acceptance review and respond. If
there are issues regarding the user fee, eCopy, or in-
formation in the packet, the review may result in a
“hold,” and the sponsor will be notiﬁed. The sponsor
then has 180 days to resolve issues. If there are no
issues (or after issues are resolved) the FDA will
assign a lead reviewer and notify the applicant
of acceptance for a complete review. FDA communi-
cations with the applicant will occur while the
device is under review to increase efﬁciency of the
review process.
The FDA assigns the times at which interactions
will occur as: 1) within 60 days of receipt of a com-
plete submission for 510(k) (i.e., 45 days afteracceptance for complete review); and 2) within 90
days of the ﬁling date for PMA (i.e., within 75 days of
acceptance for complete review).
STEP 6: REGISTER THE ESTABLISHMENT AND LIST
THE DEVICE. Once FDA approval is given, the
sponsor must register the business that will produce
and distribute the device within the United States and
“list” their device (40).
POST-APPROVAL FOLLOW-UP FOR
DRUGS AND DEVICES
DRUGS: PHASE IV STUDIES AND POST-MARKETING
REGULATORY STEPS. Following approval and mar-
keting of a drug, phase IV (“post-marketing”) studies
may be undertaken to test the drug in additional
patient populations (e.g., pediatric patients), in new
delivery modes (e.g., timed-release capsules or
transdermal patches), or for treatment of a different
medical condition. These trials must meet the same
standards as phase III clinical trials. Additional phase
IV data may include patient surveys regarding drug
side effects and other patient-reported issues (41).
The FDA’s post-market regulatory procedures
require that manufacturers report all serious and
unexpected adverse reactions to the FDA. In addition,
mechanisms allow for physicians and patients to
report issues. The Ofﬁce of Surveillance and Epide-
miology identiﬁes drug safety concerns and recom-
mends actions to improve product safety, by
monitoring the relevant publications, conducting
studies using computer databases, and watching for
signals of safety problems of marketed drugs by
reviewing adverse event reports (42).
OFF-LABEL USE OF DRUGS. Once approved by the
FDA, the agency is empowered to regulate the mar-
keting of a drug, but not the practice of medicine.
This means that a drug company may only advertise
and market a drug for the speciﬁc purpose approved
by the FDA. Marketing or advertising a drug for
another purpose requires an application for a “label-
ing change” through the FDA (43). An FDA-approved
drug can legally be used by a qualiﬁed physician in
ways other than those approved by the FDA, so long
as the physician is well-informed, bases the new use
of the drug on sound medical evidence, and main-
tains records of its use. According to the FDA, “Use of
a marketed product in this manner when the intent is
the ‘practice of medicine’ does not require the sub-
mission of an Investigational New Drug Application
(IND), Investigational Device Exemption (IDE) or
review by an institutional review board” (43). Local
institutions can, however establish policies that
FIGURE 1 Similar Processes in Drug and Device Approval
HDE ¼ human device exemption; IDE ¼ investigational device exemption; IND ¼ investigational new drug; PMA ¼ pre-market approval.
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IRB, although it is uncommon for them to do so.
DEVICES: POST-MARKET REGULATIONS AND PROCESSES.
After a device goes to market, federal regulations
require hospitals, health professionals, and other
users of medical devices to report patient incidents
involving the device, both to the manufacturer and to
the FDA if the incident results in serious patient
injury, death, or other patient-adverse experiences
(44). Hospitals are additionally required to track use
of certain devices if failure of the device could result
in a serious adverse health outcome. The FDA may
require manufacturers to put post-marketing sur-
veillance plans in place (45) and to submit a
post-marketing surveillance report if the device
meets any of the following criteria (46):
 its failure would be reasonably likely to have
serious adverse health consequences;
 it is expected to have signiﬁcant use in pediatric
populations;
 it is intended to be implanted in the body for more
than one year; or it is intended to be a life-sustaining or life-
supporting device used outside a device user
facility.
At times, a PMA or HDE (and other new device
protocols) may be approved by the FDA conditional
on the future completion of certain clinical studies.
These studies are then tracked by the CDRH to ensure
completion and continued safety and efﬁcacy of the
device. A recent study suggests, however, that such
conditional approvals may be problematic; the
investigators found that as long as 5 years after
approval, only 18% of devices that had been approved
by the FDA conditional on the completion of further
clinical studies in the post-market period had actually
undergone such studies (47). Another 18% had not
been subjected to any post-market trials. While some
such trials would take more than 3 to 5 years to
complete and therefore may be pending, the
investigators questioned whether they in fact will
ever be completed.
Banned dev ices . In extreme cases, the FDA may
decide to ban a device from the Federal Register if it
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286determines, on the basis of all available data and in-
formation, and after consulting with the appropriate
classiﬁcation panel, that a device intended for human
use presents deception (such as adulteration or mis-
labeling) or risk of illness or injury that cannot be
corrected by a change in labeling (48).
SUMMARY
Drug and device approval pathways share common
characteristics (Figure 1). Each has special pre-
submission opportunities for collaboration with the
FDA. Each has 3 main pathways to approval. For each
there is a main pathway requiring signiﬁcant clinical
evidence of efﬁcacy and safety (the Investigational
New Drug Application and the PMA, respectively),
and a pathway for emergency use (the emergencyinvestigational new drug and the Emergency Use
notiﬁcation, respectively). Deciding which path to
initiate is only the ﬁrst of a series of challenges that
face the investigator. Early and regular communica-
tion with the FDA is encouraged to avoid pitfalls and
problems that may waste time and resources.
Streamlining processes for drug and device
approval is an important goal, but doing so without
compromising the FDA’s ability to ensure the safety
and efﬁcacy of new drugs and devices for patients
will remain a continuing challenge.
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